RT Journal Article
SR Electronic
T1 Proteomic and Metabolomic Characterization of COVID-19 Patient Sera
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.07.20054585
DO 10.1101/2020.04.07.20054585
A1 Shen, Bo
A1 Yi, Xiao
A1 Sun, Yaoting
A1 Bi, Xiaojie
A1 Du, Juping
A1 Zhang, Chao
A1 Quan, Sheng
A1 Zhang, Fangfei
A1 Sun, Rui
A1 Qian, Liujia
A1 Ge, Weigang
A1 Liu, Wei
A1 Liang, Shuang
A1 Chen, Hao
A1 Zhang, Ying
A1 Li, Jun
A1 Xu, Jiaqin
A1 He, Zebao
A1 Chen, Baofu
A1 Wang, Jing
A1 Yan, Haixi
A1 Zheng, Yufen
A1 Wang, Donglian
A1 Zhu, Jiansheng
A1 Kong, Ziqing
A1 Kang, Zhouyang
A1 Liang, Xiao
A1 Ding, Xuan
A1 Ruan, Guan
A1 Xiang, Nan
A1 Cai, Xue
A1 Gao, Huanhuan
A1 Li, Lu
A1 Li, Sainan
A1 Xiao, Qi
A1 Lu, Tian
A1 Zhu, Yi
A1 Liu, Huafen
A1 Chen, Haixiao
A1 Guo, Tiannan
YR 2020
UL http://medrxiv.org/content/early/2020/04/07/2020.04.07.20054585.abstract
AB Severe COVID-19 patients account for most of the mortality of this disease. Early detection and effective treatment of severe patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model correctly classified severe patients with an accuracy of 93.5%, and was further validated using ten independent patients, seven of which were correctly classified. We identified molecular changes in the sera of COVID-19 patients implicating dysregulation of macrophage, platelet degranulation and complement system pathways, and massive metabolic suppression. This study shows that it is possible to predict progression to severe COVID-19 disease using serum protein and metabolite biomarkers. Our data also uncovered molecular pathophysiology of COVID-19 with potential for developing anti-viral therapies.Competing Interest StatementThe research group of T.G. is partly supported by Tencent, Thermo Fisher Scientific, SCIEX and Pressure Biosciences Inc. C.Z., Z.K., Z.K. and S.Q. are employees of DIAN Diagnostics.Clinical TrialChiCTR2000031365Funding StatementThis work is supported by grants from Westlake Special Program for COVID-19 (2020), and Tencent foundation (2020), National Natural Science Foundation of China (81972492, 21904107, 81672086), Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society Advancement Program (20190101A04).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or the supplementary material. The proteomics and metabolomics data are deposited in ProteomeXchange Consortium (https://www.iprox.org/). Project ID: IPX0002106000. All the data will be publicly released upon publication.